Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Pierre, Boisselier"'
Autor:
Kerstin Faravel PT, MSc, Marta Jarlier MSc, Pierre Senesse MD, PhD, Marie-Eve Huteau MSc, Chloé Janiszewski MSc, Anne Stoebner MD, Pierre Boisselier MD
Publikováno v:
Integrative Cancer Therapies, Vol 22 (2023)
Externí odkaz:
https://doaj.org/article/aef7928f8135485f87fa6848c77c6cd0
Autor:
Kerstin Faravel PT, MSc, Marta Jarlier MSc, Pierre Senesse MD, PhD, Marie-Eve Huteau MSc, Chloé Janiszewski MSc, Anne Stoebner MD, Pierre Boisselier MD
Publikováno v:
Integrative Cancer Therapies, Vol 22 (2023)
Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) induces side-effects, including trismus, which impairs quality of life by causing difficulty to eat, speak, and maintain good oral hygiene, and by altering social life. Given the wide
Externí odkaz:
https://doaj.org/article/cd1b6919c70a487d871991d0ab18174d
Autor:
Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois, Philippe Lambin
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), eit
Externí odkaz:
https://doaj.org/article/3d19c81b16c745a58482aa1902edf103
Autor:
Lotte van der Weijst, David Azria, Patrick Berkovic, Pierre Boisselier, Erik Briers, Renée Bultijnck, Jenny Chang-Claude, Ananya Choudhury, Gilles Defraene, Sylvian Demontois, Rebecca M. Elliott, Dawn Ennis, Corinne Faivre-Finn, Marzia Franceschini, Tommaso Giandini, Alexandra Giraldo, Sara Gutiérrez-Enríquez, Carsten Herskind, Daniel S. Higginson, Sarah L. Kerns, Kerstie Johnson, Maarten Lambrecht, Philippe Lang, Mónica Ramos, Tiziana Rancati, Andreas Rimner, Barry S. Rosenstein, Dirk De Ruysscher, Ahmed Salem, Claudia Sangalli, Petra Seibold, Paloma Sosa Fajardo, Elena Sperk, Hilary Stobart, Holly Summersgill, Veerle Surmont, Paul Symonds, Begoña Taboada-Valladares, Christopher J. Talbot, Ana Vega, Liv Veldeman, Marlon R. Veldwijk, Tim Ward, Adam Webb, Catharine M.L. West, Yolande Lievens
Publikováno v:
Radiotherapy and Oncology, 176, 127-137. Elsevier Ireland Ltd
BACKGROUND AND PURPOSE: To investigate the association between clinician-scored toxicities and patient-reported health-related quality of life (HRQoL), in early-stage (ES-) and locally-advanced (LA-) non-small cell lung cancer (NSCLC) patients receiv
Autor:
Justine A. Barletta, Steven D. Gilday, Michelle Afkhami, Diana Bell, Theresa Bocklage, Pierre Boisselier, Nicole G. Chau, Nicole A. Cipriani, Valerie Costes-Martineau, Ronald A. Ghossein, Hans J. Hertzler, Alan M. Kramer, Sewanti Limaye, Carlos A. Lopez, Tony L. Ng, Annikka Weissferdt, Bin Xu, Songlin Zhang, Christopher A. French
Publikováno v:
American Journal of Surgical Pathology. 46:1706-1715
NUT carcinoma (NC) is a rare subtype of squamous cell carcinoma defined by NUTM1 rearrangements encoding NUT fusion oncoproteins (the most frequent fusion partner being BRD4 ) that carries a very poor prognosis, with most patients dying in under 1 ye
Autor:
Cecile Le Pechoux, Nicolas Pourel, Fabrice Barlesi, Delphine Lerouge, Delphine Antoni, Bruno Lamezec, Ursula Nestle, Pierre Boisselier, Eric Dansin, Amaury Paumier, Karine Peignaux, François Thillays, Gerard Zalcman, Jeannick Madelaine, Eric Pichon, Anne Larrouy, Armelle Lavole, Delphine Argo-Leignel, Marc Derollez, Corinne Faivre-Finn, Matthew Q Hatton, Oliver Riesterer, Emilie Bouvier-Morel, Ariane Dunant, John G Edwards, Pascal Alexandre Thomas, Olaf Mercier, Aurelie Bardet
Publikováno v:
The Lancet Oncology. 23:104-114
Autor:
Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabeta Gherga, France Nguyen, Cédrik Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Lars Damstrup, Philippa Crompton, Abdallah Ennaji, Kathrin Gollmer, Heidi Nauwelaerts, Jean Bourhis
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2023, 183, pp.24-37. ⟨10.1016/j.ejca.2022.12.015⟩
Tao, Yungan; Sun, Xu-Shan; Pointreau, Yoann; Le Tourneau, Christophe; Sire, Christian; Kaminsky, Marie-Christine; Coutte, Alexandre; Alfonsi, Marc; Calderon, Benôit; Boisselier, Pierre; Martin, Laurent; Miroir, Jessica; Ramee, Jean-Francois; Delord, Jean-Pierre; Clatot, Florian; Rolland, Frederic; Villa, Julie; Magne, Nicolas; Elicin, Olgun; Gherga, Elisabeta; ... (2023). Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European journal of cancer, 183, pp. 24-37. Elsevier 10.1016/j.ejca.2022.12.015
European Journal of Cancer, 2023, 183, pp.24-37. ⟨10.1016/j.ejca.2022.12.015⟩
Tao, Yungan; Sun, Xu-Shan; Pointreau, Yoann; Le Tourneau, Christophe; Sire, Christian; Kaminsky, Marie-Christine; Coutte, Alexandre; Alfonsi, Marc; Calderon, Benôit; Boisselier, Pierre; Martin, Laurent; Miroir, Jessica; Ramee, Jean-Francois; Delord, Jean-Pierre; Clatot, Florian; Rolland, Frederic; Villa, Julie; Magne, Nicolas; Elicin, Olgun; Gherga, Elisabeta; ... (2023). Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. European journal of cancer, 183, pp. 24-37. Elsevier 10.1016/j.ejca.2022.12.015
International audience; Introduction: We report long-term efficacy and overall survival (OS) results from a randomised, double-blind, phase 2 study (NCT02022098) investigating xevinapant plus standard-of-care chemoradiotherapy (CRT) vs. placebo plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211a0df94cec42ecc06dd2e0c99d51be
Autor:
Morgan Michalet, Ons Bettaïeb, Samia Khalfi, Asma Ghorbel, Simon Valdenaire, Pierre Debuire, Norbert Aillères, Roxana Draghici, Mailys De Méric De Bellefon, Marie Charissoux, Pierre Boisselier, Sylvain Demontoy, Alexis Marguerit, Morgane Cabaillé, Marie Cantaloube, Aïcha Keskes, Touria Bouhafa, Marie-Pierre Farcy-Jacquet, Pascal Fenoglietto, David Azria, Olivier Riou
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 291
Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021.
Autor:
Kerstin Faravel, Anne Stoebner, Marta Jarlier, Marie-Eve Huteau, Chloé Janiszewski, Pierre Senesse, Pierre Boisselier
Publikováno v:
Kinésithérapie, la Revue. 23:20
Autor:
Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau, Yoann Pointreau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabeta Gherga, France Nguyen, Cedrick Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Angela Zubel, Claudio Zanna, Silvano Brienza, Philippa Crompton, Elisabeth Rouits, Kathrin Gollmer, Sergio Szyldergemajn, Jean Bourhis
Publikováno v:
The Lancet Oncology. 21:1173-1187
Summary Background Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through casp